HR
DMK

Hayden Royal’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Hayden Royal’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-572
Closed -$44K – 213
2021
Q2 		$44K Buy
572
+103
+22% +$6.27K 0.02% 206
2021
Q1 		$31K Buy
469
+98
+26% +$7.63K 0.02% 206
2020
Q4 		$13K Hold
371
– – 0.01% 328
2020
Q3 		$20K Sell
371
-36
-9% -$2.13K 0.01% 206
2020
Q2 		$15.3K Hold
407
– – 0.01% 167
2020
Q1 		$10.2K Buy
407
+178
+78% +$7.55K 0.01% 219
2019
Q4 		$12.3K Buy
+229
New +$11.1K 0.01% 216

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return

Hayden Royal's DMK Position: Q3 2021 in Review

Hayden Royal sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2021, closing a stake of 572 shares — an estimated $44K sold.

Hayden Royal first reported a position in DMK in Q4 2019 and held it in 7 quarters. The position peaked at $44K in Q2 2021. 52 funds tracked by Wall St. Rank hold DMK as of Q3 2021.

  • Hayden Royal reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2021 after selling out during the quarter.
  • Hayden Royal sold 572 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2021, an estimated $44K.
  • Hayden Royal first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2019 and held it in 7 quarters.
  • Hayden Royal's DMK Pharmaceuticals Corporation Common Stock position peaked at $44K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2021.

Based on Hayden Royal's 13F filing for Q3 2021, filed 15 Nov 2021.